| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CHICAGO, November 2, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September 30, 2026. |
| 23 Oct 2026 |
8-K: Other Events
On October 23, 2026, Tempus AI, Inc. (“Tempus”) announced that it had entered into a series of agreements with Bristol-Myers Squibb Company (“BMS”) and Pathos AI, Inc. (“Pathos”) to expand the use of Tempus’s de-identified multimodal rea... |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CHICAGO, July 30, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026. |
| 20 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of July 20, 2026, is by and among Tempus AI, Inc., a Nevada corporation (“Parent”), Aviary Development, Inc., a Delaware corporation and a direct, wholly-owned Subsidiary of ... |
| 20 Jul 2026 |
8-K: Regulation FD Disclosure
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform |
| 22 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Tempus AI, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 21, 2026. In accordance with the Company’s amended and restated certificate of incorporation, stockholders of the Company’s Class ... |
| 13 May 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more
INDENTURE dated as of May 12, 2026 between TEMPUS AI, INC., a Nevada corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association, as tr... |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CHICAGO, May 5, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CHICAGO, February 24, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2025. |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CHICAGO, January 11, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year ended D... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CHICAGO, November 4, 2025 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended September 30, 2025. |
| 27 Aug 2025 |
8-K: Other Events
We have acted as local Nevada counsel to Tempus AI, Inc., a Nevada corporation (the “Company”), in connection with the registration, for resale from time to time by the applicable selling stockholder(s) identified in the Prospectus Suppl... |
| 08 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CHICAGO, August 8, 2025 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended June 30, 2025. |
| 03 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
This FOURTH AMENDMENT TO CREDIT AGREEMENT, dated as of June 30, 2025 (this “Amendment”), is by and among Tempus AI, Inc., a Delaware corporation (f/k/a Tempus Labs, Inc.) (the “Borrower”), each other Loan Party signatory hereto, Ares Cap... |
| 23 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Tempus AI, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on May 20, 2025. In accordance with the Company’s amended and restated certificate of incorporation, stockholders of the Company’s Class ... |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CHICAGO, May 6, 2025 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. |
| 23 Apr 2025 |
8-K: Other Events
On April 17, 2025 (the “Effective Date”), Tempus AI, Inc. (“Tempus”), AstraZeneca AB (“AstraZeneca”), and Pathos AI, Inc. (“Pathos”) entered into a series of agreements regarding both the development of a foundational large multimodal mo... |
| 24 Feb 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CHICAGO, February 24, 2025 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024. |
| 03 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
This THIRD AMENDMENT TO CREDIT AGREEMENT AND FIRST AMENDMENT TO GUARANTEE AND COLLATERAL AGREEMENT, dated as of February 3, 2025 (this “Amendment”), is by and among Tempus AI, Inc., a Delaware corporation (f/k/a Tempus Labs, Inc.) (the “... |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CHICAGO, January 13, 2025 – Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and ... |
Loading...